131 related articles for article (PubMed ID: 36657979)
21. [
Lin R; Lin Z; Chen Z; Zheng S; Zhang J; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2960-2971. PubMed ID: 35462566
[TBL] [Abstract][Full Text] [Related]
22. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
23. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
24. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
25.
Chen Y; Zheng S; Zhang J; Yao S; Miao W
Ann Nucl Med; 2022 Jul; 36(7):610-622. PubMed ID: 35551610
[TBL] [Abstract][Full Text] [Related]
26. Radiopharmaceutical Formulation and Preclinical Testing of
Hörmann AA; Klingler M; Rangger C; Mair C; Decristoforo C; Uprimny C; Virgolini IJ; von Guggenberg E
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34208516
[TBL] [Abstract][Full Text] [Related]
27. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
28. Comparison of [
Chen H; Pang Y; Wu J; Zhao L; Hao B; Wu J; Wei J; Wu S; Zhao L; Luo Z; Lin X; Xie C; Sun L; Lin Q; Wu H
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1820-1832. PubMed ID: 32222810
[TBL] [Abstract][Full Text] [Related]
29. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
30. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.
Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M
Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942
[TBL] [Abstract][Full Text] [Related]
31. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
33. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
34. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
35. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract][Full Text] [Related]
37.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
38. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
39. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
40. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]